Seizure risk in brain tumor patients with conversion to generic levetiracetam

Journal of Neuro-Oncology

Volumn 98, Issue 1, 2010, Pages 137-141

  Armstrong, Terri S ^a,b   Choi, Shauna ^b   Walker, Julie ^b   Gilbert, Mark R ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antiepileptic drugs; Primary brain tumors; Seizures

Indexed keywords

DEXAMETHASONE; ETIRACETAM; GABAPENTIN; PHENOBARBITAL; PHENYTOIN; SORAFENIB; TEMOZOLOMIDE;

ADD ON THERAPY; ADULT; ANTICONVULSANT THERAPY; ARTICLE; BRAIN TUMOR; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; COMPLEX PARTIAL SEIZURE; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; GLIOBLASTOMA; GRAND MAL SEIZURE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MONOTHERAPY; NEUROIMAGING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PATIENT COMPLIANCE; RISK FACTOR; SEIZURE;

ADULT; ANTICONVULSANTS; BRAIN NEOPLASMS; DRUGS, GENERIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRACETAM; SEIZURES;

EID: 77953617450     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-0066-3     Document Type: Article

References (17)

1. MJ Glantz BF Cole PA Forsyth LD Recht PY Wen MC Chamberlain SA Grossman JG Cairncross 2000 Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 54 1886 1893 1:STN:280: DC%2BD3c3osVWhsA%3D%3D 10822423
2. A Beaumont IR Whittle 2000 The pathogenesis of tumour associated epilepsy Acta Neurochir (Wien) 142 1 15 10.1007/s007010050001 1:STN:280: DC%2BD3c7ivFeksA%3D%3D
3. BE Gidal T Tomson 2008 Debate: substitution of generic drugs in epilepsy: is there cause for concern? Epilepsia 49 Suppl 9 56 62 10.1111/j.1528-1167. 2008.01927.x 19087118
4. G Kramer BJ Steinhoff M Feucht M Pfafflin TW May 2007 Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss branches of the ILAE Epilepsia 48 609 611 10.1111/j.1528-1167.2007.01084-1.x 17346253 (Pubitemid 46365177)
5. RT Burkhardt IE Leppik K Blesi S Scott SR Gapany JC Cloyd 2004 Lower phenytoin serum levels in persons switched from brand to generic phenytoin Neurology 63 1494 1496 1:STN:280:DC%2BD2crjsVChug%3D%3D 15505173
6. TE Welty PR Pickering BC Hale R Arazi 1992 Loss of seizure control associated with generic substitution of carbamazepine Ann Pharmacother 26 775 777 1:STN:280:DyaK38zgsFCgsA%3D%3D 1611158
7. J Feely M Barry 2005 Adverse drug interactions Clin Med 5 19 22 15745192
8. F Andermann MS Duh A Gosselin PE Paradis 2007 Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes Epilepsia 48 464 469 10.1111/j.1528-1167.2007. 01007.x 1:CAS:528:DC%2BD2sXksVaktLc%3D 17346246 (Pubitemid 46365174)
9. K Liow GL Barkley JR Pollard CL Harden CW Bazil 2007 Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy Neurology 68 1249 1250 10.1212/01.wnl.0000259400.30539.cc 1:STN:280:DC%2BD2s3ivFCisA%3D%3D 17438213 (Pubitemid 46625968)
10. Foundation of America E: In their own words: epilepsy patients' experiences changing the formulation of the drugs they use to prevent seizures. Chicago
11. KY Yap WK Chui A Chan 2008 Drug interactions between chemotherapeutic regimens and antiepileptics Clin Ther 30 1385 1407 10.1016/j.clinthera.2008.08. 011 1:CAS:528:DC%2BD1cXhtF2rtLfI 18803983
12. KL Rascati KM Richards MT Johnsrud TA Mann 2009 Effects of antiepileptic drug substitutions on epileptic events requiring acute care Pharmacotherapy 29 769 774 10.1592/phco.29.7.769 1:CAS:528:DC%2BD1MXhtVCht7%2FO 19558250
13. WM Zachry 3rd QD Doan JD Clewell BJ Smith 2009 Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes Epilepsia 50 493 500 10.1111/j.1528-1167. 2008.01703.x 1:CAS:528:DC%2BD1MXksF2jsL4%3D 18616554
14. W Van Paesschen H Hauman L Lagae 2009 The use of generic medication in epilepsy: a review of potential issues and challenges Eur J Paediatr Neurol 13 87 92 10.1016/j.ejpn.2008.07.007 18790656
15. MJ Berg RA Gross KJ Tomaszewski WM Zingaro LS Haskins 2008 Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures Neurology 71 525 530 10.1212/01.wnl.0000319958.37502.8e 1:CAS:528:DC%2BD1cXpsVClsbs%3D 18695164
16. MJ Berg RA Gross LS Haskins WM Zingaro KJ Tomaszewski 2008 Generic substitution in the treatment of epilepsy: patient and physician perceptions Epilepsy Behav 13 693 699 10.1016/j.yebeh.2008.06.001 18589000
17. BE Gidal 2009 Bioequivalence of antiepileptic drugs: how close is close enough? Curr Neurol Neurosci Rep 9 333 337 10.1007/s11910-009-0050-5 19515287